Webinar Overview
Join us for an insightful webinar on the PIPAc project, an innovative approach to pharmaceutical manufacturing that integrates AI, NMR, flow chemistry, and 3D-printed modular reactors. Attendees will explore how AI-driven process control optimizes chemical reactions in real time, while in-line NMR provides precise monitoring of active pharmaceutical ingredient (API) synthesis. Continuous flow chemistry combined with compact, 3D-printed reactors enable mobile, resource-efficient production, supporting rapid scale-up and flexible deployment. Gain in-depth insights into the convergence of automation, analytical technologies, and advanced reactor design shaping modern pharmaceutical production.
Tuesday, 4 November 2025
5 PM CET / 11 AM EST
Key Learning Points
- Enhanced Process Control: Learn how AI, NMR, and PAT enable real-time monitoring, optimizing reactions and ensuring efficient, reliable API production.
- Scalable and Flexible Production: Understand how modular 3D-printed reactors and continuous flow chemistry support rapid scale-up and mobile manufacturing.
- Innovative Applications: Explore advanced applications of flow chemistry, 3D-printed reactors, and AI-driven analytics to drive innovation and improve pharmaceutical API processes.
What to Expect
Discover how the PIPAc project integrates AI, NMR, flow chemistry, and 3D-printed reactors for compact, mobile API manufacturing. Learn about real-time process monitoring, continuous flow optimization, modular reactor design, and case studies showcasing efficient, scalable, and safe pharmaceutical production, providing actionable insights for modern API synthesis
Who should attend?
This webinar is designed for pharmaceutical scientists, bioprocess engineers, and quality assurance professionals, as well as anyone involved in pharmaceutical manufacturing and development. Attendees will gain practical insights to enhance process control, ensure product quality, and explore innovative NMR, PAT, and AI applications.
Speakers
Alejandro Bara-Estaún, PhD
Solution Product Manager for (bio)Process Analytical Technology, Bruker Biospin
Alejandro Bara Estaun obtained his Ph.D. in Inorganic Chemistry at the University of Bath (UK) in collaboration with Bristol University and Evonik (Germany). He then undertook a two-year postdoctoral position at Bruker, leading the PIPAc project in collaboration with Alysohpil, Novalix, and De Dietrich. Recently, he transitioned into the role of Solution Product Manager for (bio)Process and Process Analytical Technology within Bruker’s Biopharma and Applied (BPA) division.
Philippe Robin
Co-founder and CEO of Alysophil
Philippe Robin is the co-founder and CEO of Alysophil, a Strasbourg-based company developing solutions in continuous-flow chemistry enhanced by artificial intelligence for process control. Alysophil aims to improve the efficiency and sustainability of chemical production. Under his leadership, the company has launched projects such as Chempocket, modular micro-factories designed for flexible chemical synthesis, and PIPAc, a program dedicated to pharmaceutical processes, carried out with partners including De Dietrich, Bruker, and Novalix. Philippe Robin focuses on applying new technologies to support the chemical industry’s transition toward more flexible and responsible production models.
Luis Carrillo
Managing Director, De Dietrich France Dijon SAS
Luis Carrillo is the Managing Director of De Dietrich Group’s subsidiary in Dijon, dedicated to developing engineering solutions through the integration of both in-house and third-party products. Dijon also serves as the hub for the Group’s innovation program, within which the PIPA’c project plays a pivotal role as a cornerstone for the future commercial development of these solutions. A chemist by training, Luis earned his degree from the University of Barcelona (Spain) and later completed a Master at IESE Business School. Luis Carrillo has been with the De Dietrich Group for more than 10 years, holding various positions across the organization. Luis Carrillo is committed to advancing sustainable innovation and strengthening the Group’s leadership in chemical engineering solutions.
Guillaume Bentzinger, PhD
Flow & Process department, Novalix
Guillaume Bentzinger joined Novalix as a Junior Project Manager in 2018 in the Synthetic Chemistry department. In 2019, he transitioned to the Process & Flow department where he advanced to Project Manager and has been actively contributing to the development of flow chemistry at Novalix. He is leading the development of the chemistry under flow conditions for the PIPAc project. Guillaume Bentzinger studied organic chemistry in Strasbourg, at the IUT Robert Schuman Technical Institute, and later at the European School of Chemistry, Polymers and Materials (ECPM). In 2016, he completed his PhD in medicinal chemistry under the supervision of Professor Pascal Sonnet and Dr. Alexandra Dassonville-Klimpt at the University of Picardie Jules Verne in Amiens. In 2017, he pursued postdoctoral research in medicinal chemistry at Almac Discovery and the University of Belfast, under the supervision of Dr. Hugues Miel.